Background We evaluated whether rivaroxaban alone or in combination with aspirin would
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In
this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic
vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once
daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome
was a composite of cardiovascular death, stroke, or myocardial infarction. The study was …

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin
would be more effective than aspirin alone for secondary cardiovascular prevention.
METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable
atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin
(100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The
primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction …